{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:46Z","timestamp":1786980586159,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-026-04229-6","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:52:34Z","timestamp":1773723154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitors in combination with standard treatment versus standard treatment alone for newly diagnosed glioblastoma: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-081X","authenticated-orcid":false,"given":"Valdemir Aquino","family":"de Freitas Neto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-7280","authenticated-orcid":false,"given":"Jos\u00e9 Henrique N\u00f3brega","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8879-2854","authenticated-orcid":false,"given":"Leonardo","family":"de Carvalho Melikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3943-4213","authenticated-orcid":false,"given":"Jos\u00e9 C\u00e9lio","family":"de Aquino Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7003-6548","authenticated-orcid":false,"given":"Marcus Vinicius Lucena","family":"Gondim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6315-1787","authenticated-orcid":false,"given":"Luiz Eduardo Souto","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-2474","authenticated-orcid":false,"given":"Hugo Rafael","family":"de Souza e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"4229_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neurooncology 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neurooncology"},{"key":"4229_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, Van Den Bent MJ et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"4229_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, Van Den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"4229_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neurooncology 22:1073\u20131113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106","journal-title":"Neurooncology"},{"key":"4229_CR5","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/ijms25052529","volume":"25","author":"E Obrador","year":"2024","unstructured":"Obrador E, Moreno-Murciano P, Oriol-Caballo M et al (2024) Glioblastoma Therapy: Past, Present and Future. IJMS 25:2529. https:\/\/doi.org\/10.3390\/ijms25052529","journal-title":"IJMS"},{"key":"4229_CR6","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/biomedicines13081882","volume":"13","author":"F Esparza-Salazar","year":"2025","unstructured":"Esparza-Salazar F, Murguiondo-P\u00e9rez R, Cano-Herrera G et al (2025) Glioblastoma: A Multidisciplinary Approach to Its Pathophysiology, Treatment, and Innovative Therapeutic Strategies. Biomedicines 13:1882. https:\/\/doi.org\/10.3390\/biomedicines13081882","journal-title":"Biomedicines"},{"key":"4229_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY et al (2020) Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 70:299\u2013312. https:\/\/doi.org\/10.3322\/caac.21613","journal-title":"CA Cancer J Clin"},{"key":"4229_CR8","doi-asserted-by":"publisher","first-page":"15037","DOI":"10.3390\/ijms242015037","volume":"24","author":"E Agosti","year":"2023","unstructured":"Agosti E, Zeppieri M, De Maria L et al (2023) Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements. IJMS 24:15037. https:\/\/doi.org\/10.3390\/ijms242015037","journal-title":"IJMS"},{"key":"4229_CR9","doi-asserted-by":"publisher","unstructured":"Tang C, Wang X, Soh H et al (2014) Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? Cancer Immunol Res 2:831\u2013838. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0069","DOI":"10.1158\/2326-6066.CIR-14-0069"},{"key":"4229_CR10","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Accessed December 16, 2025. [Online]. Available: https:\/\/training.cochrane.org\/handbook"},{"key":"4229_CR11","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"4229_CR12","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"4229_CR13","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A et al (2022) Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated. promoter Neuro-Oncology 24:1935\u20131949. https:\/\/doi.org\/10.1093\/neuonc\/noac116","journal-title":"promoter Neuro-Oncology"},{"key":"4229_CR14","doi-asserted-by":"publisher","first-page":"vdaf032","DOI":"10.1093\/noajnl\/vdaf032","volume":"7","author":"NF Brown","year":"2025","unstructured":"Brown NF, McBain C, Brazil L et al (2025) Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial. Neuro-Oncology Adv 7:vdaf032. https:\/\/doi.org\/10.1093\/noajnl\/vdaf032","journal-title":"Neuro-Oncology Adv"},{"key":"4229_CR15","doi-asserted-by":"publisher","first-page":"vdad124","DOI":"10.1093\/noajnl\/vdad124","volume":"5","author":"H-W Sim","year":"2023","unstructured":"Sim H-W, Wachsmuth L, Barnes EH et al (2023) NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro-Oncology Adv 5:vdad124. https:\/\/doi.org\/10.1093\/noajnl\/vdad124","journal-title":"Neuro-Oncology Adv"},{"key":"4229_CR16","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. https:\/\/doi.org\/10.1136\/bmj.l4898. BMJ l4898","DOI":"10.1136\/bmj.l4898"},{"key":"4229_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/cells9020263","volume":"9","author":"J Adhikaree","year":"2020","unstructured":"Adhikaree J, Moreno-Vicente J, Kaur AP et al (2020) Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells 9:263. https:\/\/doi.org\/10.3390\/cells9020263","journal-title":"Cells"},{"key":"4229_CR18","doi-asserted-by":"publisher","first-page":"1584688","DOI":"10.3389\/fphar.2025.1584688","volume":"16","author":"M Fu","year":"2025","unstructured":"Fu M, Xue B, Miao X, Gao Z (2025) Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies. Front Pharmacol 16:1584688. https:\/\/doi.org\/10.3389\/fphar.2025.1584688","journal-title":"Front Pharmacol"},{"key":"4229_CR19","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol 29:3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"4229_CR20","doi-asserted-by":"publisher","unstructured":"Jia Z, Li X, Yan Y et al (2022) Exploring the relationship between age and prognosis in glioma: rethinking current age stratification. BMC Neurol 22:350. https:\/\/doi.org\/10.1186\/s12883-022-02879-9","DOI":"10.1186\/s12883-022-02879-9"},{"key":"4229_CR21","doi-asserted-by":"publisher","first-page":"624780","DOI":"10.3389\/fonc.2021.624780","volume":"11","author":"A Karimi","year":"2021","unstructured":"Karimi A, Alilou S, Mirzaei HR (2021) Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab. Front Oncol 11:624780. https:\/\/doi.org\/10.3389\/fonc.2021.624780","journal-title":"Front Oncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04229-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:02:21Z","timestamp":1773766941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04229-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4229"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04229-6","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"286"}}